ArticleFrontiers in medicine2025
Prevalence of genital and extragenital sexually transmitted infections among women of reproductive age with and without HIV in the Southern US: results from the study of treatment and reproductive outcomes.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sexually transmitted infections (STI) are highly prevalent among women of reproductive age (WRA) and increase the risk of HIV acquisition and transmission. However, the burden of extragenital STIs is understudied among WRA in the US. Estimates of disease are urgently needed among women living with (WWH) and without HIV (WWOH), to inform sex-specific screening guidelines. Methods: Cross-sectional data from cisgender WWH and WWOH, ages 18-45 years, enrolled in the Study of Treatment and Reproductive Outcomes (STAR) from March 2021 to August 2023 at six Southern US sites was analyzed. Sociodemographic and behavioral assessments were performed using structured interviewer-administered questionnaires. Nucleic-acid amplification tests were performed, regardless of symptoms, on self-collected urine, rectal, and pharyngeal swabs to detect trichomoniasis, chlamydia, and gonorrhea. Sociodemographic characteristics and risk factors were compared by STI status and concordance between genital and extragenital STIs was examined. Results: Among the 543 participants, 55.2% WWH, mean age was 34.0 (SD ± 7.14) years old, most (72.5%) were non-Hispanic Black, 41.6% had multiple sexual partners, and 85.6% engaged in unprotected sex. Overall, 1.9% tested positive for genital chlamydia, 2.9% rectal chlamydia, 0.6% oropharyngeal chlamydia, 3.4% genital gonorrhea, 1.2% rectal gonorrhea, 1.3% oropharyngeal gonorrhea, and 12.2% trichomoniasis. Genital chlamydia was associated with rectal chlamydia ( Discussion: Prevalence of genital, rectal, oral chlamydia (1.8%, 2.8%, and 0.6%) and gonorrhea (3.3%, 1.1%, and 1.3%), and genital trichomoniasis (11.4%) are high among WRA with and without HIV. The adverse impact for women's reproductive health and HIV transmission highlights the importance of extragenital STI testing for women in areas of high prevalence of STIs in the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.